Literature DB >> 11483599

Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

J Sampath1, D Sun, V J Kidd, J Grenet, A Gandhi, L H Shapiro, Q Wang, G P Zambetti, J D Schuetz.   

Abstract

The most frequently expressed drug resistance genes, MDR1 and MRP1, occur in human tumors with mutant p53. However, it was unknown if mutant p53 transcriptionally regulated both MDR1 and MRP1. We demonstrated that mutant p53 did not activate either the MRP1 promoter or the endogenous gene. In contrast, mutant p53 strongly up-regulated the MDR1 promoter and expression of the endogenous MDR1 gene. Notably, cells that expressed either a transcriptionally inactive mutant p53 or the empty vector showed no endogenous MDR1 up-regulation. Transcriptional activation of the MDR1 promoter by mutant p53 required an Ets binding site, and mutant p53 and Ets-1 synergistically activated MDR1 transcription. Biochemical analysis revealed that Ets-1 interacted exclusively with mutant p53s in vivo but not with wild-type p53. These findings are the first to demonstrate the induction of endogenous MDR1 by mutant p53 and provide insight into the mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483599     DOI: 10.1074/jbc.M103429200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  90 in total

1.  Direct regulation of BCL-2 by FLI-1 is involved in the survival of FLI-1-transformed erythroblasts.

Authors:  Isabelle Lesault; Christine Tran Quang; Jon Frampton; Jacques Ghysdael
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

2.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

3.  Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity.

Authors:  Timo Quante; Benjamin Otto; Marie Brázdová; Iva Kejnovská; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Cell Cycle       Date:  2012-08-21       Impact factor: 4.534

4.  Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.

Authors:  Heidi Sankala; Catherine Vaughan; Jing Wang; Sumitra Deb; Paul R Graves
Journal:  Arch Biochem Biophys       Date:  2011-05-20       Impact factor: 4.013

Review 5.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

6.  Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.

Authors:  Xuetian Yue; Fangnan Wu; Yanchen Li; Juan Liu; Michael Boateng; Kranthi Mandava; Cen Zhang; Zhaohui Feng; Jimin Gao; Wenwei Hu
Journal:  Cell Cycle       Date:  2020-04-10       Impact factor: 4.534

7.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

8.  Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.

Authors:  Xiang Wang; Jin-xiu Chen; Yan-hui Liu; Chao You; Qing Mao
Journal:  Neurol Sci       Date:  2012-12-08       Impact factor: 3.307

9.  Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells.

Authors:  Zhenyu Ding; Li Yang; Xiaodong Xie; Fangwei Xie; Feng Pan; Jianjun Li; Jianming He; Houjie Liang
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

10.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.